{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03798028",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2014ZX09508002"
      },
      "Organization": {
        "OrgFullName": "Xijing Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis",
      "OfficialTitle": "The Effects and Safety of Mesenchymal Stem Cells in the Treatment of Moderate/Severe Rheumatoid Arthritis， a Multicenter Randomized Controlled Clinical Study"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 26, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 31, 2019",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 30, 2020",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "January 7, 2019",
      "StudyFirstSubmitQCDate": "January 7, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 9, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 7, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 9, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Xijing Hospital",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Changhai Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Southwest Hospital, China",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study evaluates the safety and therapeutic effects of single-dose human umbilical cord blood mesenchymal stem cells (UC-MSCs) on the adult patients with moderate/severe Rheumatoid Arthritis accompany with anemia or/and Interstitial pulmonary disease. Half of participants will receive UC-MSCs and keep the present medication,while the other half will receive a placebo and keep the present medication."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Rheumatoid Arthritis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "anemia",
          "Interstitial pulmonary disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "250",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "UC-MSCs treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "the participants will receive the single-dose UC-MSCs (1×10^6 cells/kg ) in combined with the present treatment.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: UC-MSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "no UC-MSCs treatment",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "the participants will receive the placebo in combined with the present treatment."
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "UC-MSCs",
            "InterventionDescription": "The UC-MSCs will be administrated by intravenous injection at the dose of 1×10^6 cells/kg.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "UC-MSCs treatment"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Improvement rate of blood routine hemoglobin (HGB) compared to baseline.",
            "PrimaryOutcomeDescription": "The HGB increases by 10g compared to the baseline is considered improvement.",
            "PrimaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Improvement rate of forced vital capacity (FVC) and/or carbon monoxide diffusing capacity (DLCO) compared to baseline.",
            "PrimaryOutcomeDescription": "FVC increases by 0.5% and DLCO increases by 10% compared to baseline are considered improvement.",
            "PrimaryOutcomeTimeFrame": "24 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70.",
            "SecondaryOutcomeDescription": "The patients achieves 20%, 50%, or 70% remission according to American College of Rheumatology (ACR) criteria.",
            "SecondaryOutcomeTimeFrame": "12 weeks and 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "White blood cell count and platelet count improved compared to the baseline.",
            "SecondaryOutcomeDescription": "White blood cell count increases to the 3.5×10^9/L and platelet count increases to 80×10^ 9.",
            "SecondaryOutcomeTimeFrame": "12 weeks and 24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement rate of blood routine hemoglobin (HGB) compared to baseline.",
            "SecondaryOutcomeDescription": "The HGB increases by 10 g compared to the baseline is considered improvement.",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement rate of forced vital capacity (FVC) and/or carbon monoxide",
            "SecondaryOutcomeDescription": "FVC increases by 0.5% and DLCO increases by 10% compared to baseline",
            "SecondaryOutcomeTimeFrame": "12 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Image improvement of lung on high resolution CT.",
            "SecondaryOutcomeDescription": "The area change of image of lung.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement of 6-minute walking distance compared to baseline.",
            "SecondaryOutcomeTimeFrame": "12 weeks and 24 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nFulfill 2010 ACR/ the European League Against Rheumatism (EULAR) classification criteria or the 1987 ACR classification criteria.\nAge limits:18 to 70 years old.\nFreely given informed consent.\nDisease Activity Score (DAS) 28≥3.2或 Simple Disease Activity Index (SDAI)>11.0或 Clinical Disease Activity Index (CDAI) >10.0.\nHemoglobin < 90 g/L and/or interstitial lung disease shown in high resolution CT.\nPoor response to current treatment. The current treatment refers to receive the medicines (including Leflunomide, Methotrexate, Sulphasalazine, Hydroxychloroquine, Cyclosporine A,and Tacrolimus, alone or in combination ) for 3 months, and maintain the stable-dose of drugs for at least 1 month.\nMore than 3 months and a stable dose for at least 1 month are required if glucocorticoid is used. The dose of glucocorticoid is less than or equal to10mg/ day of prednisone.\n\nExclusion Criteria:\n\nParticipants who received glucocorticoid therapy by intra-articular injection within 1 week.\nGlucocorticoid that participants received is more than 10 mg/day of prednisone within 1 months.\nComplication with other connective tissue disease (except for Sjogren syndrome) .\nParticipants with chronic and acute infection (bacteria, virus and parasite,etc.).\nParticipants with acute and chronic tuberculosis infection.\nMalignant tumors or participants with a family history of malignant tumors.\nParticipants have a family history of allergic conditions.\nParticipants infected by Hepatitis B Virus(HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus （HIV）.\nParticipants suffer from central nervous system demyelinating disease or multiple sclerosis (MS) currently or in the past.\nParticipants received live vaccines with 3 months.\nDrug abuse and alcoholism.\nParticipants with severe mental or neurological disorders that affect informed consent and/or the presentation or observer of adverse events.\nParticipants with pregnant or in breast-feeding, and patients who has a pregnancy plan within 1 year.\nParticipants received stem cell therapy in the past.\nParticipants received any biological agents within 3 months.\nAnemia (such as anemia with dysplasia) and interstitial lung disease for other reasons.\nParticipants with cardiovascular and cerebrovascular damage, such as thrombosis.\nParticipants taking drugs that affect the test for blood and lung.\nParticipants taking any traditional Chinese medicine.\nParticipants taking immune modulators such as Transfer Factor, Thymosin and Intravenous Immunoglobulin (IVIG), and so on.\nOther cases that participants are considered by investigator that they did not meet the requirements for enrollment.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Ping Zhu, Doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-29-84773951",
            "CentralContactEMail": "zhuping@fmmu.edu.cn"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Xijing Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Xi'an",
            "LocationState": "Shaanxi",
            "LocationZip": "710032",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Ping Zhu",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "862984773951",
                  "LocationContactPhoneExt": "862984773951",
                  "LocationContactEMail": "zhuping@fmmu.edu.cn"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001168",
            "ConditionMeshTerm": "Arthritis"
          },
          {
            "ConditionMeshId": "D000001172",
            "ConditionMeshTerm": "Arthritis, Rheumatoid"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007592",
            "ConditionAncestorTerm": "Joint Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000012216",
            "ConditionAncestorTerm": "Rheumatic Diseases"
          },
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3628",
            "ConditionBrowseLeafName": "Arthritis",
            "ConditionBrowseLeafAsFound": "Arthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3632",
            "ConditionBrowseLeafName": "Arthritis, Rheumatoid",
            "ConditionBrowseLeafAsFound": "Rheumatoid Arthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3222",
            "ConditionBrowseLeafName": "Anemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18965",
            "ConditionBrowseLeafName": "Lung Diseases, Interstitial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9773",
            "ConditionBrowseLeafName": "Joint Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          }
        ]
      }
    }
  }
}